scholarly journals A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012

2013 ◽  
Vol 20 (2) ◽  
Author(s):  
A. Mamo ◽  
M. Cardoso Nogueira ◽  
G. Batist ◽  
M. Palumbo ◽  
L. Panasci ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Retrospective Analysis ◽  
Cancer Patients ◽  
General Hospital ◽  
Life Experience ◽  
Real Life ◽  
Jewish General Hospital ◽  
Colorectal Cancer Patients

scholarly journals Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data

2020 ◽  
Vol 148 (2) ◽  
pp. 296-306
Author(s):  
Patricia A. H. Hamers ◽  
Marloes A. G. Elferink ◽  
Rebecca K. Stellato ◽  
Cornelis J. A. Punt ◽  
Anne M. May ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Survival Time ◽  
Cancer Patients ◽  
Real Life ◽  
Life Data ◽  
Real Life Data ◽  
Colorectal Cancer Patients ◽  
Multiple Scenarios

scholarly journals Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients

2020 ◽  
Vol 9 (6) ◽  
pp. 1772
Author(s):  
Matthias Unseld ◽  
Sebastian Fischöder ◽  
Mathias Jachs ◽  
Magdalena Drimmel ◽  
Alexander Siebenhüner ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adverse Events ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Real Life ◽  
Surrogate Marker ◽  
University Hospital ◽  
Rank Test ◽  
Line Treatment ◽  
Colorectal Cancer Patients

The nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib significantly improved survival in metastatic colorectal cancer patients (mCRC). Both treatments are characterized by different treatment-related adverse events but detailed analyses of predictive side effects are rare. In this retrospective, observational, real-life study, clinical data on mCRC patients treated with trifluridine/tipiracil or regorafenib at the Medical University of Vienna, Austria and the University Hospital Zurich, Switzerland were collected. The correlation between adverse events and response or survival rates were calculated performing Fisher’s exact test and log-rank test, respectively. Common adverse events of any grade included fatigue (52%), nausea/vertigo (34%), anemia (26%), and leukopenia (22%) in trifluridine/tipiracil patients and fatigue (42%), hand-foot-skin syndrome (36%) and hoarseness (34%) in patients upon regorafenib treatment. In trifluridine/tipiracil patients the prevalence of leukopenia (p = 0.044) and weight loss (p = 0.044) was prognostic, whereas leukopenia (p = 0.044) and neutropenia (p = 0.043) predicted PFS. The disease control rate was not significantly affected. In regorafenib-treated patients, the prevalence of nausea (p = 0.001) was prognostic, while oral mucositis predicted PFS (p = 0.032) as well as the DCR (p = 0.039). In conclusion, we underline the efficacy of trifluridine/tipiracil and regorafenib in the real-life setting. We describe predictive adverse events like neutropenia/leukopenia, which might be used as surrogate marker in anticancer therapy beyond second line treatment.

Sign in / Sign up

Export Citation Format

Share Document